SPARC, Tripoint ink licensing pact for Elepsia XR tablets in US
"Elepsia XR can bring down the daily pill burden significantly and will be an alternative treatment option for patients suffering with epilepsy," said Anil Raghavan, CEO of SPARC.
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Tuesday said it has granted exclusive licence to Tripoint Therapeutics LLC, USA, to commercialise its novel product Elepsia XR tablets in the US. These tablets are indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older."Under terms of the licence agreement, SPARC will be...
New Delhi: Sun Pharma Advanced Research Company (SPARC) on Tuesday said it has granted exclusive licence to Tripoint Therapeutics LLC, USA, to commercialise its novel product Elepsia XR tablets in the US.
These tablets are indicated as adjunctive therapy for the treatment of partial onset seizures in patients 12 years of age and older.
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd